Morning Market Losers

shares dipped 35.39 percent to $13.58 on beloranib partial clinical hold.

shares fell 25.99 percent to $19.86 after the company announced positive topline Phase 3 clinical results for IV Solithromycin in the treatment of community-acquired bacterial pneumonia.

tumbled 20.14 percent to $1.15 after the company priced $15 share offering at $1 per share.

declined 18.20 percent to $21.44 after the company lowered its Q3 earnings forecast and issued a weak sales outlook.

dropped 13.44 percent to $43.33. Spirit Airlines raised its Q3 operating margin guidance. For 2016, capacity growth is now projected at the lower end of previous outlook range. Morgan Stanley downgraded Spirit Airlines from Overweight to Equal-weight and lowered the price target from $66.00 to $53.00.

shares fell 8.08 percent to $0.910 after the company priced 1.5 million shares at $0.70 per share.

shares declined 6.44 percent to $69.01 on its earnings report. Earnings of $0.86 per share came in below $0.88 estimate; revenue of $996.29 million fell short of expectations for earnings around $1.03 billion.

shares dropped 3.69 percent to $39.45 after the company priced 5.5 million share offering for gross proceeds of $211.8 million.

shares fell 3.50 percent to $213.88 after the company reported downbeat Q3 earnings and lowered its FY15 forecast.